GLTO Galecto, Inc. Stock Quote

GLTO [NASD]

Index	-	P/E	-	EPS (ttm)	-1.40	Insider Own	10.10%	Shs Outstand	25.26M	Perf Week	-5.73%
Market Cap	139.36M	Forward P/E	-	EPS next Y	-2.10	Insider Trans	0.00%	Shs Float	25.20M	Perf Month	-26.00%
Income	-34.80M	PEG	-	EPS next Q	-0.46	Inst Own	52.50%	Short Float	0.19%	Perf Quarter	-53.75%
Sales	-	P/S	-	EPS this Y	19.40%	Inst Trans	-	Short Ratio	1.38	Perf Half Y	-
Book/sh	6.55	P/B	0.90	EPS next Y	56.30%	ROA	-	Target Price	-	Perf Year	-
Cash/sh	6.95	P/C	0.85	EPS next 5Y	47.60%	ROE	-	52W Range	5.77 - 17.99	Perf YTD	-52.68%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-67.09%	Beta	-
Dividend %	-	Quick Ratio	30.40	Sales past 5Y	-	Gross Margin	-	52W Low	2.60%	ATR	0.47
Employees	28	Current Ratio	30.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	28.24	Volatility	7.45% 6.73%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	30.60%	Profit Margin	-	Rel Volume	4.88	Prev Close	6.12
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 29 BMO	Payout	-	Avg Volume	34.73K	Price	5.92
Recom	1.20	SMA20	-7.05%	SMA50	-35.20%	SMA200	-50.62%	Volume	169,365	Change	-3.27%

Nov-23-20

Initiated

SVB Leerink

Outperform

$27

Nov-23-20

Initiated

Credit Suisse

Outperform

$29

Nov-23-20

Initiated

BofA Securities

Buy

$21

Apr-15-21 08:00AM	Galectin-3 has a key role in Gastric Cancer GlobeNewswire
Mar-29-21 08:30AM	Galecto Reports Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update GlobeNewswire
Mar-23-21 10:26AM	UPDATE: Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139 GlobeNewswire
08:30AM	Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139 GlobeNewswire
Mar-15-21 07:30AM	Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications GlobeNewswire -5.61%
Feb-09-21 08:00AM	Galecto to Present at Upcoming Investor Conferences GlobeNewswire
Jan-29-21 01:33AM	We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth Simply Wall St.
Jan-08-21 08:00AM	Galecto Appoints Anne Prener to its Board of Directors GlobeNewswire
Jan-04-21 04:01PM	Galecto to Take Part in Two Panel Discussions at the LifeSci Partners 10th Annual Healthcare Corporate Access Event GlobeNewswire
Dec-11-20 08:06AM	Galecto Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update GlobeNewswire
Nov-30-20 08:00AM	Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing Marked Impact on Several IPF Biomarkers GlobeNewswire
Nov-23-20 04:01PM	Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors GlobeNewswire
Oct-29-20 01:28PM	Leslies Pops 30%, Allegro Jumps 41% in IPO Debuts Barrons.com
Oct-28-20 09:10PM	Galecto Announces Pricing of Initial Public Offering GlobeNewswire

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience